OliX Pharmaceuticals,Inc (226950.KQ)
KRW 18430.0
(-6.07%)
KRW 18430.0
(-6.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 52.48 Billion KRW | -21.01% |
| 2022 | 66.44 Billion KRW | -1.21% |
| 2021 | 67.26 Billion KRW | 102.44% |
| 2020 | 33.22 Billion KRW | 877.26% |
| 2019 | 3.39 Billion KRW | 386.45% |
| 2018 | 698.93 Million KRW | -76.42% |
| 2017 | 2.96 Billion KRW | 14.35% |
| 2016 | 2.59 Billion KRW | 87.39% |
| 2015 | 1.38 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 64.89 Billion KRW | 23.63% |
| 2024 Q2 | 66.1 Billion KRW | 1.87% |
| 2023 Q1 | 68.41 Billion KRW | 2.97% |
| 2023 FY | 52.48 Billion KRW | -21.01% |
| 2023 Q3 | 60.61 Billion KRW | -7.93% |
| 2023 Q2 | 65.83 Billion KRW | -3.78% |
| 2023 Q4 | 52.48 Billion KRW | -13.4% |
| 2022 Q2 | 67.75 Billion KRW | -1.59% |
| 2022 FY | 66.44 Billion KRW | -1.21% |
| 2022 Q4 | 66.44 Billion KRW | -5.38% |
| 2022 Q3 | 70.22 Billion KRW | 3.65% |
| 2022 Q1 | 68.84 Billion KRW | 2.36% |
| 2021 Q4 | 67.26 Billion KRW | 67.11% |
| 2021 Q1 | 36.61 Billion KRW | 10.19% |
| 2021 Q2 | 38.8 Billion KRW | 5.99% |
| 2021 Q3 | 40.25 Billion KRW | 3.73% |
| 2021 FY | 67.26 Billion KRW | 102.44% |
| 2020 Q4 | 33.22 Billion KRW | 884.22% |
| 2020 FY | 33.22 Billion KRW | 877.26% |
| 2020 Q1 | 2.63 Billion KRW | -22.53% |
| 2020 Q2 | 2.85 Billion KRW | 8.35% |
| 2020 Q3 | 3.37 Billion KRW | 18.29% |
| 2019 Q4 | 3.39 Billion KRW | 11.93% |
| 2019 FY | 3.39 Billion KRW | 386.45% |
| 2019 Q3 | 3.03 Billion KRW | -18.77% |
| 2019 Q2 | 3.73 Billion KRW | 17.25% |
| 2019 Q1 | 3.18 Billion KRW | 915.33% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 Q4 | 314.09 Million KRW | 0.0% |
| 2018 FY | 698.93 Million KRW | -76.42% |
| 2017 FY | 2.96 Billion KRW | 14.35% |
| 2016 FY | 2.59 Billion KRW | 87.39% |
| 2015 FY | 1.38 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 69.028% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -2691.435% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 30.649% |
| Bioneer Corporation | 80.61 Billion KRW | 34.885% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -162.62% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 61.33% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 46.343% |
| Helixmith Co., Ltd | 73.55 Billion KRW | 28.642% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 95.091% |
| Medy-Tox Inc. | 137.14 Billion KRW | 61.726% |
| Peptron, Inc. | 16.36 Billion KRW | -220.662% |
| Amicogen, Inc. | 248.12 Billion KRW | 78.846% |
| Genexine, Inc. | 79.68 Billion KRW | 34.128% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -79.291% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -27.151% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 51.515% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | 28.182% |
| SillaJen, Inc. | 19.4 Billion KRW | -170.549% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 70.691% |
| Genomictree Inc. | 7.81 Billion KRW | -571.881% |
| MedPacto, Inc. | 9.56 Billion KRW | -448.721% |
| D&D Pharmatech | 23.98 Billion KRW | -118.835% |
| EASY BIO,Inc. | 105.86 Billion KRW | 50.421% |
| GI Innovation, Inc. | 9.63 Billion KRW | -444.707% |